Bacterial skin infections are common presentations to both general practice and the emergency department.
The optimal treatment for purulent infections such as boils and carbuncles is incision and drainage. Antibiotic therapy is not usually required.
Most uncomplicated bacterial skin infections that require antibiotics need 5–10 days of treatment.
There is a high prevalence of purulent skin infections caused by community-acquired (non multiresistant) methicillin-resistant Staphylococcus aureus. It is therefore important to provide adequate antimicrobial coverage for these infections in empiric antibiotic regimens.
Introduction
It is important to have a good understanding of the common clinical manifestations and pathogens involved in bacterial skin infections to be able to manage them appropriately. The type of skin infection depends on the depth and the skin compartment involved. The classification and management of these infections are outlined in Table 1.
Table 1 - Therapeutic approach to common bacterial skin infections
Infection
Likely
pathogens
Management
Impetigo
Staphylococcus aureus
Streptococcus pyogenes
Mild or localised disease:
wash crusts
topical mupirocin
Multiple lesions or recurrent disease:
cultures to guide treatment
oral antibiotics (dicloxacillin/cephalexin/trimethoprim plus
sulfamethoxazole) for up to 10 days
intravenous antibiotics if no improvement
for recurrent infection due to S. aureus consider decolonisation
Advice and education of household members to
reduce transmission:
avoid contact with lesions
wash hands regularly, particularly after touching lesions
Boils and
carbuncles
S. aureus
S. pyogenes
Incision and drainage most important step in
management:
culture and susceptibility testing for lesions
antibiotics if spreading cellulitis or systemic symptoms
ooral
dicloxacillin/cephalexin for 5 days
ooral
clindamycin, or trimethoprim plus sulfamethoxazole for
community-acquired-MRSA for 5 days
Folliculitis
S. aureus
S. pyogenes
Pseudomonas aeruginosa
Treatment usually supportive
Warm compresses or topical mupirocin
In severe infection treat as per impetigo
Cellulitis
and erysipelas
S. aureus
Beta-haemolytic streptococci
Examine for predisposing factors
Consider unusual exposures (seeTable 2) – broaden
antibiotic therapy if this is the case
Culture and susceptibility testing for lesions,
tissue or blood
Elevate limb
Treat underlying predisposing skin infection e.g.
tinea
Mild disease:
oral dicloxacillin/cephalexin/clindamycin for 5–10 days
oral phenoxymethylpenicillin if culture is positive or clinical
presentation of S. pyogenes
Severe disease or systemic features:
intravenous flucloxacillin/cephazolin/vancomycin
Consider decolonisation or prophylactic
antibiotics with recurrent disease
Periorbital cellulitis
S. aureus
Streptococcus species
Haemophilus influenzaetype b
(in unvaccinated patients)
Mild disease:
oral dicloxacillin/cephalexin/clindamycin for 7 days
If suspectH.
influenzaetype b infection (unvaccinated,
< 5yrs old):
oral amoxycillin plus clavulanate, or cefuroxime for 7 days
Severe disease or systemic features:
treat as orbital cellulitis
Orbital cellulitis
S. aureus
Streptococcusspecies
H. influenzaetype b (in
unvaccinated patients)
Anaerobic bacteria
Inpatient hospital management with urgent
surgical opinion
Blood cultures and CT scan of orbits
Intravenous antibiotics
Necrotising
fasciitis
S. aureus
S. pyogenes
Gram negatives,Clostridiumspecies
Anaerobic bacteria
Inpatient hospital management with urgent
surgical debridement
Culture and susceptibility testing of tissue
Broad-spectrum intravenous antibiotics including
clindamycin (antitoxin effect by suppressing synthesis of bacterial
endotoxins)
MRSA
methicillin-resistantStaphylococcus
aureus
Impetigo
Impetigo is a superficial bacterial infection that can develop either through direct invasion of normal skin (primary) or infection at sites of damaged skin (secondary) (Fig. 1). It is common in children and is highly contagious. There are two forms:
non-bullous or crusted impetigo – distinct yellow, crusting lesions that may be itchy. Typically involves face or extremities
bullous impetigo – usually caused by Staphylococcus aureus. Presents as bullae that rupture to form a brown crust.
Boils and carbuncles
Boils and carbuncles are associated with infection of a hair follicle and extend into subcutaneous tissue. They are tender and painful but the patient is usually systemically well. In most cases, lesions can be treated with incision and drainage alone. Antibiotic therapy is only required if there is spreading cellulitis or systemic infection.
Folliculitis
This usually presents as a crop of pustules affecting areas of moist skin with hair. It is most commonly caused by S. aureus but can also be linked to other organisms like Pseudomonas aeruginosa when associated with specific exposures like hot tubs and spas.
Cellulitis and erysipelas
Both cellulitis and erysipelas manifest as spreading areas of skin erythema and warmth. Localised infections are often accompanied by lymphangitis and lymphadenopathy. Not infrequently, groin pain and tenderness due to inguinal lymphadenitis will precede the cellulitis. Some patients can be quite unwell with fevers and features of systemic toxicity. Bacteraemia, although uncommon (less than 5%), still occurs.
Erysipelas involves the upper dermis and superficial lymphatics. Skin lesions are usually raised with a clear demarcation of infected skin. Classically, erysipelas affects the face (Fig. 2), but it can also involve other areas such as the lower limb. It is most commonly caused by Streptococcus pyogenes (group A streptococcus).
Cellulitis extends further into the deep dermis and subcutaneous tissue. It commonly involves the lower limbs (Fig. 3) and in most cases is unilateral. Bilateral lower limb cellulitis is exceedingly rare and usually reflects stasis dermatitis and does not require antibiotic treatment. Other areas of the body such as the eye and the abdominal wall can also be affected. Periorbital cellulitis involves the eyelids and does not extend into the bony orbit. Orbital cellulitis is a much more serious infection with deeper extension and impairment of vision and extraocular eye movements, often with pain.
Cellulitis is usually caused by either S. aureus or beta-haemolytic streptococci (groups A, B, C or G). Differentiating between these two organisms can help guide therapy. Streptococcal infection is usually characterised by acute onset of rapidly spreading erythema, lymphangitis and lymphadenopathy. Staphylococcal cellulitis is usually associated with purulent lesions with erythema. Cultures from wounds or blood can further help delineate the causative organism. In the absence of positive cultures however, it can be difficult to discriminate between the two and antibiotic therapy to cover both organisms (for example flucloxacillin, dicloxacillin, cephalexin, clindamycin) is often used.
Diagnostic approach to cellulitis
When evaluating a patient with cellulitis, review systemic features. Potential portals of entry for infection should also be looked for. These include:
disruption to the skin barrier, insect bites, wounds, abrasions
lymphoedema or surgical disruption of the lymphatic or venous system
peripheral vascular disease with impaired arterial supply
chronic venous insufficiency.
It is important to consider less common causes of skin infection associated with specific clinical circumstances or exposures (Table 2). In these cases, specimens should be collected for culture and sensitivity testing and treatment regimens broadened to cover likely pathogens. In difficult-to-treat or atypical infections, specialist opinion is recommended.
Table 2 - Skin infections associated with unusual exposures and clinical scenarios
Many conditions may masquerade as cellulitis (see Box 1). These conditions should always be considered in atypical cases to avoid the unnecessary use of antibiotics.
Box 1 - Non-infectious differential diagnosis for cellulitis
Stasis dermatitis
Superficial thrombophlebitis
Deep venous thrombosis
Congestive cardiac failure
Drug reactions
Insect bites
Cutaneous vasculitis
Acute gout
Necrotising skin infections
Necrotising skin infections, the best known of which is necrotising fasciitis, are a medical and surgical emergency that require prompt debridement and appropriate intravenous antibiotics. Infections can be caused by single or multiple pathogens (e.g. S. pyogenes, Gram negatives, Clostridium).
Infection usually involves the necrosis of underlying soft tissues or muscle. Typical early clinical features are induration and erythema of the affected area with pain out of proportion to overlying skin changes. As infection progresses, the skin can change colour to purple or blue and eventually breaks down to form bullae and gangrene (Fig. 4). The patient is usually quite unwell with systemic toxicity, haemodynamic instability and multi-organ failure.
Urgent hospital referral is essential in all cases. Surgical exploration is the only way to establish the diagnosis of necrotising fasciitis and is also the definitive management in all cases. Exploration also allows material to be obtained for appropriate cultures to guide antibiotic therapy.
There has been a rapid increase in the rates of community-associated multiresistant MRSA skin infections in Australia1,2 and worldwide. It is important to consider the possibility of this pathogen if contemplating empirical antibiotic therapy for bacterial skin infections (clindamycin or trimethoprim plus sulfamethoxazole). Culture and susceptibility testing of lesions should be used to guide therapy as community-associated MRSA is resistant to beta-lactam antibiotics such as flucloxacillin, dicloxacillin and the cephalosporins.
When to use topical antibiotics
According to current recommendations, topical mupirocin is only recommended in cases of mild impetigo and folliculitis. All other infections should be managed with either incision and drainage or oral and intravenous antibiotics. Topical fusidic acid monotherapy has been associated with increased fusidic acid resistance3,4 among strains of S. aureus and it is not our preference to use this on its own.
When to use oral antibiotics
Patients with no signs of systemic toxicity and uncontrolled comorbidities can usually be managed with oral antibiotics as outpatients.
When to consider hospital referral and intravenous antibiotics
Patients with severe disease who are systemically unwell will require assessment in hospital for monitoring and intravenous antibiotics. Parenteral antibiotics can either be administered as an inpatient or through an Outpatient Parenteral Antibiotic Treatment or Hospital in the Home program. Factors that would favour hospital management of cellulitis include:5
concern for deep space infection (presence of bullae, necrosis or muscle involvement)
high fevers and rigors
haemodynamic instability
suppurative wound or bite (especially on face or hand) requiring surgical drainage
lack of systemic or local response to oral antibiotics, or rising or unchanging C-reactive protein concentrations despite adequate therapy
positive blood cultures
inability to tolerate or absorb oral antibiotics.
How to manage recurrent skin infections
Recurrent cellulitis is extremely challenging. Each repeated episode of cellulitis can cause inflammation and disruption of the lymphatic system and subsequent lymphoedema. The affected limb is subsequently more prone to infection and a vicious cycle of cellulitis and limb swelling is established.
Treating the underlying cause of infection is the most important step in management. In cases of chronic lymphoedema and venous stasis, compression of the affected limb by bandaging or stockings helps to increase venous return and contractility of the lymphatic ducts, therefore decreasing swelling and cellulitis. Further supportive measures such as elevation of the limb may also confer symptomatic relief. For example in cellulitis of the leg, raising the foot higher than the hip with supportive cushions helps to reduce swelling and pain. Prophylactic long-term suppressive antibiotics offer symptomatic benefit and cost–benefit in cases of recurrent streptococcal cellulitis.6,7 Options include twice-daily oral penicillin or cephalexin.
For recurrent staphylococcal infections, decolonisation measures should be considered (Box 2).8 In difficult cases of recurrent infections despite prophylactic antibiotics, expert consultation with an infectious disease specialist is recommended.
Box 2 Suggested decolonisation regimen for
recurrent boils or staphylococcal skin infections
Treat acute lesions.
Collect nasal or perineal swabs to determine antibiotic susceptibility of Staphylococcus aureus.
Once active skin lesions resolve, eradicate staphylococcal carriage with:
mupirocin nasal ointment for 5 days
PLUS EITHER
chlorhexidine 2% or triclosan 1% wash for 5 days in showers
OR
sodium hypochlorite solution (60 mL of 6% solution per bathtub) or triclosan 2% bath oil for 5 days in baths
Do not share towels. Wash bed linen (at least weekly) and towels (after each use) in hot water and hang out to dry in the sun.
Decolonisation of household contacts is not recommended unless the measures outlined fail to prevent recurrence in the index case or contacts have a history of recurrent skin infection.
If decolonisation measures fail, repeat topical regimen together with:
oral rifampicin for 7 days
PLUS
oral dicloxacillin, fusidate sodium or trimethoprim plus sulfamethoxazole depending on susceptibility of the organism.
Bacterial
skin infections have a variety of presentations from localised, trivial
infection to rapidly progressive infection with systemic toxicity and
considerable mortality. It is important to be able to recognise and treat these
infections in the community, and in cases of severe infection to refer the
patient promptly for specialist care.
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.